KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Debt to Equity (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Debt to Equity for 18 consecutive years, with $0.88 as the latest value for Q1 2026.

  • For Q1 2026, Debt to Equity changed N/A year-over-year to $0.88; the TTM value through Mar 2026 reached $0.88, changed N/A, while the annual FY2025 figure was $0.94, 965.86% up from the prior year.
  • Debt to Equity hit $0.88 in Q1 2026 for Ionis Pharmaceuticals, down from $0.94 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.02 in Q3 2025 and bottomed at $0.02 in Q1 2023.
  • Average Debt to Equity over 5 years is $0.34, with a median of $0.13 recorded in 2024.
  • Year-over-year, Debt to Equity tumbled 79.82% in 2023 and then soared 1421.0% in 2025.
  • Ionis Pharmaceuticals' Debt to Equity stood at $0.03 in 2022, then surged by 699.23% to $0.22 in 2023, then tumbled by 60.4% to $0.09 in 2024, then soared by 965.86% to $0.94 in 2025, then dropped by 6.44% to $0.88 in 2026.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.88, $0.94, and $1.02 for Q1 2026, Q4 2025, and Q3 2025 respectively.